Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116147 | 0.84 | GPR119 (0.48) | GPR119HTTLRRK2 | |
| SCHEMBL22358127 | 0.83 | GPR119 (0.47) | GPR119HTT | |
| SCHEMBL20116639 | 0.80 | PDE4B (0.49) | GPR119HTT | |
| SCHEMBL22357886 | 0.80 | GPR119 (0.44) | GPR119HTT | |
| SCHEMBL22358020 | 0.80 | GPR119 (0.44) | GPR119HTT | |
| SCHEMBL22358218 | 0.80 | GPR119 (0.44) | GPR119HTT | |
| SCHEMBL22358472 | 0.79 | USP30 (0.48) | GPR119HTTLRRK2 | |
| SCHEMBL20676229 | 0.79 | TLR8 (0.54) | GPR119HTT | |
| SCHEMBL22358258 | 0.79 | GPR119 (0.41) | GPR119 | |
| SCHEMBL20116960 | 0.78 | GPR119 (0.43) | GPR119HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | PTGER3 1760/4885GPR119 2922/4885HTT 6/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | PTGER3 1760/4885GPR119 2922/4885HTT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.